Economic evaluations of 13-valent pneumococcal conjugate vaccine: a systematic review

References

• Wahl B, O’Brien KL, Greenbaum A, et al. Burden of streptococcus pneumoniae and haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000-15. Lancet Glob Health. 2018 Jul;6(7):e744–e757.
   PubMed Web of Science ®Google Scholar
• Song JY, Choi JY, Lee JS, et al. Clinical and economic burden of invasive pneumococcal disease in adults: a multicenter hospital-based study. BMC Infect Dis. 2013 May;4(13):202.
   Google Scholar
• Huang SS, Johnson KM, Ray GT, et al. Healthcare utilization and cost of pneumococcal disease in the United States. Vaccine. 2011 Apr 18;29(18):3398–3412.
   PubMed Web of Science ®Google Scholar
• Shiri T, Khan K, Keaney K, et al. Pneumococcal disease: a systematic review of health utilities, resource use, costs, and economic evaluations of interventions. Value Health. 2019 Nov;22(11):1329–1344.
   PubMed Web of Science ®Google Scholar
• Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in. 195 countries, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet Infect Dis. 2018 Nov;18(11):1191–1210.
   PubMed Web of Science ®Google Scholar
• Lewnard JA, Lo NC, Arinaminpathy N, et al. Childhood vaccines and antibiotic use in low- and middle-income countries. Nature. 2020 May;581(7806):94–99.
   PubMed Web of Science ®Google Scholar
• Pneumococcal conjugate vaccines in infants and children under 5 years of age: WHO position paper, February 2019. World Health Organization. https://apps.who.int/iris/bitstream/handle/10665/310968/WER9408.pdf.
   Google Scholar
• Wang Q, An J, Zhang M, et al. Pneumococcal disease immune prevention expert consensus. Chinese Journal Epidemiology. 2020;41(12):1945–1979.
   Google Scholar
• Waight PA, Andrews NJ, Ladhani SN, et al. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis. 2015 May;15(5):535–543.
   PubMed Web of Science ®Google Scholar
• Picazo JJ, Ruiz-Contreras J, Casado-Flores J, et al. Impact of 13-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in children under 15 years old in Madrid, Spain, 2007 to 2016: the HERACLES clinical surveillance study. Vaccine. 2019 Apr 10;37(16):2200–2207.
   PubMed Web of Science ®Google Scholar
• Lepoutre A, Varon E, Georges S, et al. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012. Vaccine. 2015 Jan 3;33(2):359–366.
   PubMed Web of Science ®Google Scholar
• Berman-Rosa M, O’Donnell S, Barker M, et al. Efficacy and effectiveness of the PCV-10 and PCV-13 vaccines against invasive pneumococcal disease. Pediatrics. 2020;145(4):2019–0377.
   Web of Science ®Google Scholar
• Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020 Oct 17;396(10258):1223–1249.
   PubMed Web of Science ®Google Scholar
• Li Y, Wang HQ, Furnback W, et al. The Cost-Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine in Seven Chinese Cities. Vaccines (Basel). 2021;9(11):1368.
   PubMed Web of Science ®Google Scholar
• Mangen MJJ, Rozenbaum MH, Huijts SM, et al. Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands. Eur Respir J. 2015 Nov;46(5):1407–1416.
   PubMed Web of Science ®Google Scholar
• Bakir M, Turel O, Topachevskyi O. Cost-effectiveness of new pneumococcal conjugate vaccines in Turkey: a decision analytical model. BMC Health Serv Res. 2012;12:386.
   PubMed Web of Science ®Google Scholar
• Mo X, Gai Tobe R, Liu X, et al. Cost-effectiveness and health benefits of pediatric 23-valent pneumococcal polysaccharide vaccine, 7-valent pneumococcal conjugate vaccine and forecasting 13-valent pneumococcal conjugate vaccine in China. Pediatr Infect Dis J. 2016 Nov;35(11):e353–e361.
   PubMed Web of Science ®Google Scholar
• Zhou H, He JC, Wu B, et al. Cost-effectiveness analysis of routine 13-valent pneumococcal conjugate vaccinations in Chinese infants. Hum Vaccin Immunother. 2018;14(6):1444–1452.
   PubMed Web of Science ®Google Scholar
• Saokaew S, Rayanakorn A, Wu DB, et al. Cost effectiveness of pneumococcal vaccination in children in low- and middle-income countries: a systematic Review. Pharmacoeconomics. 2016 Dec;34(12):1211–1225.
   PubMed Web of Science ®Google Scholar
• Shao Y, Stoecker C. Cost-effectiveness of pneumococcal vaccines among adults over 50 years old in low- and middle-income countries: a systematic review. Expert Rev Vaccines. 2020 Dec;19(12):1141–1151.
   PubMed Web of Science ®Google Scholar
• van de Vooren K, Duranti S, Curto A, et al. Cost effectiveness of the new pneumococcal vaccines: a systematic review of European studies. Pharmacoeconomics. 2014 Jan;32(1):29–45.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009 Jul;21(339):b2535.
   Google Scholar
• Walker DG, Hutubessy R, Beutels P. WHO Guide for standardisation of economic evaluations of immunization programmes. Vaccine. 2010 Mar 8;28(11):2356–2359.
   PubMed Web of Science ®Google Scholar
• Husereau D, Drummond M, Petrou S, et al. Consolidated health economic evaluation reporting standards (CHEERS) statement. Value Health. 2013 Mar-Apr;16(2):e1–5.
   PubMed Web of Science ®Google Scholar
• Hamberg-van Reenen HH, Proper KI. van den Berg M. Worksite mental health interventions: a systematic review of economic evaluations. Occup Environ Med. 2012 Nov;69(11):837–845.
   PubMed Web of Science ®Google Scholar
• Mihalopoulos C, Chatterton ML. Economic evaluations of interventions designed to prevent mental disorders: a systematic review. Early Interv Psychiatry. 2015 Apr;9(2):85–92.
   PubMed Web of Science ®Google Scholar
• Ning GJ. Study on the burden of childhood pneumonia and the economic evaluations of an immunization program in Baiyin City Chinese center for disease control and prevention; 2017. https://kns.cnki.net/kcms/detail/detail.aspx?dbcode=CDFD&dbname=CDFDLAST2022&filename=1019196162.nh&uniplatform=NZKPT&v=jSPWW5xNOlBr7BMrZCQCRxbf7caTbVFpGCAttqp64A8Z8wj5VkMKxYP6ft5zyHNR]
   Google Scholar
• Lin L. Protective effect and health economic evaluations of 13-valent pneumococcal conjugate vaccine in children under 2 years old in Ningbo Ningbo University. 2020. https://kns.cnki.net/kcms/detail/detail.aspx?dbcode=CMFD&dbname=CMFD202201&filename=1021532021.nh&uniplatform=NZKPT&v=7AdnDso9w1YD-_5PwOIz4my9tYS5eAzA-FKn0yvJridEshIQnh6qRuwE718GBQcf]
   Google Scholar
• Kim HY, Park SB, Kang ES, et al. Cost-effectiveness of a national immunization program with the 13-valent pneumococcal conjugate vaccine compared with the 10-valent pneumococcal conjugate vaccine in South Korea. Hum Vaccin Immunother. 2021 Mar;17(3):909–918.
   PubMed Web of Science ®Google Scholar
• Perdrizet J, Santana CFS, Senna T, et al. Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants. Hum Vaccin Immunother. 2021 Apr;17(4):1162–1172.
   PubMed Web of Science ®Google Scholar
• Perdrizet J, Horn EK, Nua W, et al. Cost-effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) versus lower-valent alternatives in Filipino infants. Infect Dis Ther. 2021 Dec;10(4):2625–2642.
   PubMed Web of Science ®Google Scholar
• Wang CX, Su L, Mu QL, et al. Cost-effectiveness analysis of domestic 13-valent pneumococcal conjugate vaccine for children under 5 years of age in mainland China. Hum Vaccin Immunother. 2021 Jul;17(7):2241–2248.
   PubMed Web of Science ®Google Scholar
• Dilokthornsakul P, Kengkla K, Saokaew S, et al. An updated cost-effectiveness analysis of pneumococcal conjugate vaccine among children in Thailand. Vaccine. 2019 Jul;37(32):4551–4560.
   PubMed Web of Science ®Google Scholar
• Ezoji K, Yaghoubi M, Nojomi M, et al. Cost-effectiveness of introducing the pneumococcal conjugate vaccine for children under 5 years in the Islamic Republic of Iran. East Mediterr Health J. 2019 Oct;25(10):686–697.
   PubMed Web of Science ®Google Scholar
• Krishnamoorthy Y, Eliyas SK, Nair NP, et al. Impact and cost effectiveness of pneumococcal conjugate vaccine in India. Vaccine. 2019 Jan;37(4):623–630.
   PubMed Web of Science ®Google Scholar
• Dorji K, Phuntsho S, Pempa, et al. Towards the introduction of pneumococcal conjugate vaccines in Bhutan: a cost-utility analysis to determine the optimal policy option. Vaccine. 2018 Mar;36(13):1757–1765.
   PubMed Web of Science ®Google Scholar
• Shen KL, Wasserman M, Liu DD, et al. Estimating the cost-effectiveness of an infant 13-valent pneumococcal conjugate vaccine national immunization program in China. PLoS One. 2018;13(7):201–245.
   Web of Science ®Google Scholar
• Kuhlmann A. von der Schulenburg JMG. Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany. Eur J Health Econ. 2017 Apr;18(3):273–292.
   PubMed Web of Science ®Google Scholar
• Sundaram N, Chen C, Yoong J, et al. Cost-effectiveness of 13-valent pneumococcal conjugate vaccination in Mongolia. Vaccine. 2017 Feb;35(7):1055–1063.
   PubMed Web of Science ®Google Scholar
• Maurer KA, Chen HF, Wagner AL, et al. Cost-effectiveness analysis of pneumococcal vaccination for infants in China. Vaccine. 2016 Dec;34(50):6343–6349.
   PubMed Web of Science ®Google Scholar
• Vucina VV, Filipovic SK, Koznjak N, et al. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia. Vaccine. 2015;33:A209–A218.
   PubMed Web of Science ®Google Scholar
• Mezones-Holguin E, Canelo-Aybar C, Clark AD, et al. Cost-effectiveness analysis of 10-and 13-valent pneumococcal conjugate vaccines in Peru. Vaccine. 2015;33:A154–A166.
   PubMed Web of Science ®Google Scholar
• Kieninger MP, Caballero EG, Sosa AA, et al. Cost-effectiveness analysis of pneumococcal conjugate vaccine introduction in Paraguay. Vaccine. 2015;33:A143–A153.
   PubMed Web of Science ®Google Scholar
• Sibak M, Moussa I, El-Tantawy N, et al. Cost-effectiveness analysis of the introduction of the pneumococcal conjugate vaccine (PCV-13) in the Egyptian national immunization program, 2013. Vaccine. 2015;33:A182–A191.
   PubMed Web of Science ®Google Scholar
• Mezones-Holguin E, Bolanos-Diaz R, Fiestas V, et al. Cost-effectiveness analysis of pneumococcal conjugate vaccines in preventing pneumonia in Peruvian children. J Infect Developing Countries. 2014 Dec;8(12):1552–1562.
   Google Scholar
• Gomez JA, Tirado JC, Rojas AAN, et al. Cost-effectiveness and cost utility analysis of three pneumococcal conjugate vaccines in children of Peru. BMC public health. 2013;13:1025.
   PubMed Web of Science ®Google Scholar
• Kulpeng W, Leelahavarong P, Rattanavipapong W, et al. Cost-utility analysis of 10-and 13-valent pneumococcal conjugate vaccines: protection at what price in the Thai context? Vaccine. 2013 Jun;31(26):2839–2847.
   PubMed Web of Science ®Google Scholar
• Ayieko P, Griffiths UK, Ndiritu M, et al. Assessment of health benefits and cost-effectiveness of 10-valent and 13-valent pneumococcal conjugate vaccination in Kenyan children. PLoS One. 2013;8(6):e67324.
   PubMed Web of Science ®Google Scholar
• Hoshi SL, Kondo M, Okubo I. Economic evaluation of vaccination programme of 13-valent pneumococcal conjugate vaccine to the birth cohort in Japan. Vaccine. 2013 Jun;31(25):2762–2771.
   PubMed Web of Science ®Google Scholar
• Earnshaw SR, McDade CL, Zanotti G, et al. Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada. Bmc Infectious Diseases. 2012;12:101.
   PubMed Web of Science ®Google Scholar
• Díez-Domingo J, Ridao-López M, Gutiérrez-Gimeno MV, et al. Pharmacoeconomic assessment of implementing a universal PCV-13 vaccination programme in the Valencian public health system (Spain). Vaccine. 2011 Dec 6;29(52):9640–9648.
   PubMed Web of Science ®Google Scholar
• Robberstad B, Frostad CR, Akselsen PE, et al. Economic evaluation of second generation pneumococcal conjugate vaccines in Norway. Vaccine. 2011 Nov;29(47):8564–8574.
   PubMed Web of Science ®Google Scholar
• Mucino-Ortega E, Mould-Quevedo JF, Farkouh R, et al. Economic evaluation of a child immunization programme in Mexico based in 13-valent PCV. Value Health. 2011 Jul-Aug;14(5):S65–S70.
   PubMed Web of Science ®Google Scholar
• Uruena A, Pippo T, Betelu MS, et al. Cost-effectiveness analysis of the 10-and 13-valent pneumococcal conjugate vaccines in Argentina. Vaccine. 2011 Jul;29(31):4963–4972.
   PubMed Web of Science ®Google Scholar
• Kim SY, Lee G, Goldie SJ, et al. Economic evaluation of pneumococcal conjugate vaccination in The Gambia. Bmc Infectious Diseases. 2010;10:260.
   PubMed Web of Science ®Google Scholar
• Igarashi A, Hirose E, Kobayashi Y, et al. Cost-effectiveness analysis for PCV13 in adults 60 years and over with underlying medical conditions which put them at an elevated risk of pneumococcal disease in Japan. Expert Rev Vaccines. 2021 Sep;20(9):1153–1165.
   PubMed Web of Science ®Google Scholar
• Gouveia M, Jesus G, Ines M, et al. Cost-effectiveness of the 13-valent pneumococcal conjugate vaccine in adults in Portugal versus “no vaccination” and versus vaccination with the 23-valent pneumococcal polysaccharide vaccine. Hum Vaccin Immunother. 2019 Apr;15(4):850–858.
   PubMed Web of Science ®Google Scholar
• Biagini L, Pezzani M, Rojas R, et al. Cost-utility study of PCV13 Versus PPSV23 in adults in Chile. Value Health Reg Issues. 2018;17:194–201.
   PubMedGoogle Scholar
• Chen C, Beutels P, Newall AT. Evolution over time in the cost-effectiveness of pneumococcal conjugate vaccine (PCV13) in older Australians due to herd protection from infant vaccination. Vaccine. 2018 Apr;36(16):2057–2060.
   PubMed Web of Science ®Google Scholar
• Marbaix S, Peetermans WE, Verhaegen J, et al. Cost-effectiveness of PCV13 vaccination in Belgian adults aged 65-84 years at elevated risk of pneumococcal infection. PLoS One. 2018;13(7):e0199427.
   PubMed Web of Science ®Google Scholar
• Boccalini S, Bechini A, Gasparini R, et al. Economic studies applied to vaccines against invasive diseases: an updated budget impact analysis of age-based pneumococcal vaccination strategies in the elderly in Italy. Hum Vaccin Immunother. 2017;13(2):417–422.
   PubMed Web of Science ®Google Scholar
• Heo JY, Seo YB, Choi WS, et al. Cost-effectiveness of pneumococcal vaccination strategies for the elderly in Korea. PLoS One. 2017;12(5):e0177342.
   PubMed Web of Science ®Google Scholar
• Dirmesropian S, Wood JG, MacIntyre CR, et al. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13) in older Australians. Vaccine. 2017 Aug;35(34):4307–4314.
   PubMed Web of Science ®Google Scholar
• Rodríguez González-Moro JM, Menéndez R, Campins M, et al. Cost effectiveness of the 13-valent pneumococcal conjugate vaccination program in chronic obstructive pulmonary disease patients aged 50+ years in Spain. Clin Drug Investig. 2016 Jan;36(1):41–53.
   PubMed Web of Science ®Google Scholar
• Smith KJ, Wateska AR, Nowalk MP, et al. cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with Pneumococcal polysaccharide vaccine. JAMA J Am Med Assoc. 2012 Feb;307(8):804–812.
   PubMed Web of Science ®Google Scholar
• zhang H, Lai X, lv Y, et al. Systematic review of economic evaluations of different immunization strategies of pneumococcal conjugate vaccine in China. Chinese Health Economics. 2022;41(2):9–14.
   Google Scholar
• Slotved HC, Dalby T, Hoffmann S. The effect of pneumococcal conjugate vaccines on the incidence of invasive pneumococcal disease caused by ten non-vaccine serotypes in Denmark. Vaccine. 2016 Feb 3;34(6):769–774.
   PubMed Web of Science ®Google Scholar
• Lazarus R, Clutterbuck E, Yu LM, et al. A randomized study comparing combined pneumococcal conjugate and polysaccharide vaccination schedules in adults. Clin Infect Dis. 2011 Mar 15;52(6):736–742.
   PubMed Web of Science ®Google Scholar
• Shiramoto M, Hanada R, Juergens C, et al. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults. Hum Vaccin Immunother. 2015;11(9):2198–2206.
   PubMed Web of Science ®Google Scholar
• Drost R, van der Putten IM, Ruwaard D, et al. Conceptualizations of the Societal Perspective within Economic Evaluations: a Systematic Review. Int J Technol Assess Health Care. 2017 Jan;33(2):251–260.
   PubMed Web of Science ®Google Scholar
• Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics. 1998 Apr;13(4):397–409.
   PubMed Web of Science ®Google Scholar
• Hoang VP, Shanahan M, Shukla N, et al. A systematic review of modelling approaches in economic evaluations of health interventions for drug and alcohol problems. BMC Health Serv Res. 2016 Apr;13(16):127.
   Google Scholar
• Brennan A, Chick SE, Davies R. A taxonomy of model structures for economic evaluation of health technologies. Health Econ. 2006 Dec;15(12):1295–1310.
   PubMed Web of Science ®Google Scholar
• Løchen A, Anderson RM. Dynamic transmission models and economic evaluations of pneumococcal conjugate vaccines: a quality appraisal and limitations. Clin Microbiol Infect. 2020 Jan;26(1):60–70.
   PubMed Web of Science ®Google Scholar
• Wu DB, Chang CJ, Huang YC, et al. Cost-effectiveness analysis of pneumococcal conjugate vaccine in Taiwan: a transmission dynamic modeling approach. Value Health. 2012 Jan-Feb;15(1 Suppl):S15–9.
   PubMed Web of Science ®Google Scholar
• Jmr G-M, Menendez R, Campins M, et al. Cost effectiveness of the 13-valent pneumococcal conjugate vaccination program in chronic obstructive pulmonary disease patients aged 50+years in Spain. Clin Drug Investig. 2016 Jan;36(1):41–53.
   PubMed Web of Science ®Google Scholar
• Husereau D, Drummond M, Augustovski F, et al. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMC Health Serv Res. 2022 Jan 27;22(1):114.
   PubMed Web of Science ®Google Scholar